Currently ongoing grants Health, EIC

Horizon Work Programme 2021-2027

immutol

GUIDE.MRD
Project 101080562101112066- HORIZON-JU-IHI-2022-01-03

GUIding multi-moDal thErapies against MRD by liquid biopsies - GUIDE.MRD

Starting Date: 1 May 2023
Grant Agreement: 101112066
Project Cost: € 34.452.565
EC Funding: € 17.660.955

immutol

IMMUTOL
Project 101080562- HORIZON-HLTH-2022-DISEASE-06-two-stage

Advanced Antigen-Specific Dendritic Cell-Based Therapy to Re-establish Tolerance in Immune-Mediated Diseases

Starting Date: 1 May 2023
Grant Agreement: 101080562
Project Cost: € 5.999.340

proto

PROTO
Project 101095635- HORIZON-HLTH-2022-STAYHLTH-02-01

Advanced PeRsOnalized Therapies for Osteoarthritis –Tackling inflammation to improve patient outcomes

Starting Date: 1 January 2023
Grant Agreement: 101095635
Project Cost: € 7.447.875

t-fitness

T-FITNESS
Project 101070740 - HORIZON-EIC-2021-PATHFINDERCHALLENGES-01

Fine-Tuning T Cell Networks of Exhaustion by Synthetic Sensors

Starting Date: 1 September 2022
Grant Agreement: 101070740
Project Cost: € 3.789.472

genetiga

geneTIGA
Project 101057438 - HORIZON-HLTH-2021-TOOL-06

Gene-edited T cells combating IgA Nephropathy

Starting Date: 1 July 2022
Grant Agreement: 101057438
Project Cost: € 5.736.859

restore

TwistedNano
Project 101046424 - HORIZON-EIC-2021-PATHFINDEROPEN-01

Twisted nanophotonic technology for integrated chiroptical sensing of drugs on a chip

Starting Date: 1 April 2022
Grant Agreement: 101046424
Project Cost: € 3.197.925

 

Currently ongoing grants RIA, CSA, IMI

H2020 Work Programme 2018-2020

restore

RESTORE
CSA - Large Scale Research Initiative

RESTORE Health by Advanced Therapies (Advanced Therapy Medicinal Products and Biologized Medical Devices) – ALL for Advanced Therapies – with Passion – For Patients’

Starting Date: 1 March 2019
Grant Agreement: 820292
Project Cost: € 1.000.000
EU Contribution: € 1.000.000

reshape

ReSHAPE
RIA BHC 09-2018

Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches - from Advanced Technology Developments to First-in-Human Trials

Starting Date: 1 January 2019
Grant Agreement: 825392
Budget: € 13.137.396,25

necessity

NECESSITY
IMI Grant

New Clinical Endpoints in primary Sjögren’s Syndrome: an Interventional Trial based on stratifying patients

Starting Date: 1 January 2019
Grant Agreement: 806975
Project Cost: € 15.485.964,84
EU Contribution: € 8.200.000,00

liverscreen

LIVERSCREEN
RIA BHC 30-2019

Screening for liver fibrosis - population-based study across European countries

Starting Date: 1 January 2020
Grant Agreement: 847989

hdm-fun

HDM-FUN
RIA BHC14-2019

Host directed medicine in invasive fungal infection

Starting Date: 1 January 2020
Grant Agreement: 847507

hipgen

HIPGEN
RIA - Research and Innovation action

Placenta-expanded adherent stromal cells (plx-pad) as an innovative therapy for improving recovery and survival following hip fracture arthroplasty - HIPGEN, a multicenter phase III trial

Starting Date: 1 January 2018
Grant Agreement: 779293

pace

PACE
RIA - Research and Innovation action

A multicenter phase III study using HLA-unmatched allogeneic placenta-derived stromal cells (PLX-PAD) for the treatment of severe critical limb ischemia accompanied by mechanistic studies

Starting Date: 1 January 2017
Grant Agreement: 733006

liverhope

LIVERHOPE
RIA - Research and Innovation action

Simvastatin and Rifaximin as new therapy for patients with decompensated cirrhosis

Starting Date: 1 January 2017
Grant Agreement: 731875

 

Currently ongoing grants MSCA - ITN - DN

H2020 Work Programme 2018-2020 | Horizon Work Programme 2021-2027

tolerate

TOLERATE
MSCA-DN

An integrated approach to restore tolerance in autoimmune disease

Starting Date: 1 October 2022
Grant Agreement: 101072729
Budget: € 2.109.650,40

instruct

INsTRuCT
MSCA-ITN (ETN)

INnovative Training in Myeloid Regulatory Cell Therapy

Starting Date: 1 January 2020
Grant Agreement: 860003
Budget: € 4.021.026,84

educ8

EDUC8
MSCA-ITN (ETN)

Early Stage Researchers EDUCational Program on Factor VIII Immunogenicity

Starting Date: 1 April 2020
Grant Agreement: 859974

integrata

INTEGRATA
MSCA-ITN (ETN)

Integrating chemical and biological approaches to target NAD production and signaling in cancer

Starting Date: 1 November 2018
Grant Agreement: 813284
Budget: € 3.738.573,00


success-rate

Innovation Acta
H2020 Success rate

 

   


Innovation Acta S.r.l. | Via delle Province, 1 - 53100 Siena - Italy | VAT number: 13201341008

© 2020 Innovation Acta - All rights reserved

PRIVACY

Innovation Acta S.r.l.
VAT number: 13201341008

+39 0577 1652729
  +39 366 3746125

  info@innovationacta.eu
  acta_srl@pec.it

Registered office and operational headquarter:
Via delle Province, 1 - 53100 Siena - Italy


Branch office:
Via D.A. Azuni, 9 - 00196 Roma - Italy